WALTHAM, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it will host an Investor Day on Friday, June 8, 2018 in New York City starting at 8:00 a.m. ET. Members of the Radius leadership team will provide business updates and facilitate discussions with external osteoporosis opinion leaders, Dr. Tamara Vokes, Dr. Douglas Beall and Dr. Paul Miller.
|Event:||Radius Investor Day: Advancing Treatment Care for Osteoporosis|
|Date:||Friday, June 8, 2018|
|Time:||8:00 — 8:30 a.m.|
08:30 a.m. — 12:00 p.m.
|Breakfast and Registration|
Presentations and Q&A
|Location:||Lotte NY Palace Hotel, 455 Madison Avenue, New York, NY — Hubbard I - Boardroom|
|Key Speakers: ||Tamara Vokes, MD, University of Chicago Medical Center|
Douglas P. Beall, MD, The Spine Fracture Institute, Oklahoma
Paul Miller, MD, Colorado Center for Bone Research at Panorama Orthopedics & Spine Center
|Radius Health:||Jesper Hoeiland, President & CEO|
Pepe Carmona, CFO
Gary Hattersley, PhD, Chief Scientific Officer
Bruce Mitlak, MD, Vice President, Clinical Development
Joe Kelly, Senior Vice President, Sales & Marketing
Amanda Mott, Senior Vice President, Market Access
Elhan Webb, CFA, Vice President Investor Relations and External Communications
This event is intended for analysts and institutional investors only. To reserve a spot, please reply to Alex Fudukidis at firstname.lastname@example.org or Elhan Webb, CFA, Head of Investor Relations and External Communications at email@example.com.
A live webcast of the presentation will be available by visiting the Investors section of Radius' website at http://ir.radiuspharm.com/events.cfm. A replay of the webcast will be archived on Radius' website for 30 days following the presentation.
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
Investor Relations Contact:
Elhan Webb, CFA